This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Alnylam Elevates Dr. Pushkal Garg to Lead Unified Research and Development Organization, Signaling Strategic Expansion into Next Phase of RNAi Therapeutics Innovation Alnylam Pharmaceuticals , a global leader in RNA interference (RNAi) therapeutics, has announced the promotion of Pushkal Garg, M.D.,
Sanofi and Regeneron’s Dupixent Shows Superiority over Xolair in First-Ever Head-to-Head Phase 4 Study in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps and Co-existing Asthma Sanofi and Regeneron Pharmaceuticals, Inc.
This field allowed me the privilege of tending to children in the hospital and building long-term relationships with them and their families. Pooja transitioned to the pharmaceutical industry to broaden her impact on patient care, leveraging her expertise to help develop innovative cancer treatments.
The pharmaceutical industry is facing pressure on multiple fronts: increasingly scarce early-stage funding, growing competition from Chinese biotech companies, and a traditional drug discovery process that remains inefficient and expensive.”
FDA Grants Accelerated Approval to Regeneron’s Lynozyfic™ (linvoseltamab-gcpt) for Relapsed or Refractory Multiple Myeloma Regeneron Pharmaceuticals has secured a critical milestone in oncology drug development with the U.S. This connection triggers targeted T-cell activation and destruction of cancerous plasma cells.
As a proof of concept, a drug designed to target a newly discovered biological node is showing efficacy in treating rare genetic diseases in the kidney, the eye, and the brain and is now making its way to clinical trials in collaboration with a pharmaceutical partner.
There are varied opinions about site consolidation, but I would like to add some perspective: Pharmaceutical companies routinely buy up small pharmaceutical and biotech companies and add them to their portfolio. Site consolidation is much the same. It has its pros and cons, but I will speak to the positives of such consolidation.
3,20 These crises drive high rates of emergency department use and hospital admissions, significantly disrupting education, employment and family life. 24 Hospitals can also play a role, as shown by Harbor-UCLA Medical Center. Use of Disease-Modifying Treatments in Patients with Sickle Cell Disease. JAMA Network Open.
Expanding Access and Personalization of Prostate Cancer Treatment Christine Roth, Executive Vice President of Global Product Strategy and Commercialization and a member of Bayer’s Pharmaceuticals Leadership Team, emphasized the strategic significance of this milestone.
0004]The synthesis of Landiolol 1 is disclosed in US 5013734 , JP 3302647 , CN 100506814 , JP 2539734 and Chemical & Pharmaceutical Bulletin 1992, 40 (6) 1462-1469. Furthermore, landiolol demonstrated a positive clinical impact regarding ventilation-free days, ICU-free days and hospital-free days. June 1992). 40 (6): 14629.
P.S. Todays article is adapted from Chapter 3 of DCIs forthcoming 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , which will be available to preorder next week at special introductory pricing. Payers adoption of white baggingand providers push backreflect the ongoing battle for oncology margin in U.S.
Over the years, Advarra has reviewed a wide range of clinical research studies and worked every day alongside leading pharmaceutical manufacturers, medical researchers, and healthcare institutions. Without clinical research, these medical breakthroughs would remain out of reach for patients.
Kristen Quick, Director at Perficient, shared her insights on the transformative potential of Salesforce Life Sciences Cloud for pharmaceutical and med tech organizations, highlighting its ability to drive innovation and improve outcomes.
My goal is not only to tell the story of a pharmaceutical staple but to share what my decades-long work in evidence synthesis in epidemiology has taught me about researching scientific history. In this article, Eichengrün stated that he was appointed, in 1895, to establish and manage a pharmaceutical laboratory at Bayer.
Topics will include: The competitive landscape of retail pharmacy , with exclusive market data from DCI and 46brooklyn Key economic trends among leading PBMs and their impact on the market PBMs controversial effect on pharmacy and how theyre shaping the industry The medications driving pharmacy profits and the ones bringing financial pain The benefits (..)
Bill Cassidy’s report calls on Congress to improve the transparency of the drug discount program in a move praised by pharmaceutical companies and criticized by hospitals.
However, buy-and-bill appears to have rebounded substantially at hospitals. As I explain below, this resurgence likely reflects the success of vertically-integrated hospital/specialty pharmacy/physician mega-systems against the large insurer/PBM/specialty pharmacy/provider mega-organizations. d/b/a Drug Channels Institute.
Jude Children’s Research Hospital announced a new pediatric-focused fellowship today. The initiative aims to help address the critical shortage of top young scientists who often seek more prevalent opportunities in adult cancer research or the pharmaceutical sector. […]
I am pleased to announce our new 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. pharmaceutical distribution industry. contains new data on hospital acquisitions and consolidation activity. Section 6.1.6.
I am pleased to announce our new 2021–22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. pharmaceutical distribution industry. So, you can find out what your customers, partners, and competitors are reading.
This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. pharmacy industry—act as contract pharmacies for the hospitals and federal grantees that participate in the 340B program.
The battle for the specialty patient pits hospitals against insurers—and their respective specialty pharmacies. Hospitals, however, lose profits and face higher costs. Hospitals, however, lose profits and face higher costs. As you will see, UnitedHealthcare has been especially aggressive in accelerating channel change.
R327 was studied against several Gram-negative and Gram-positive microbial species, including the ESKAPE pathogens, a group of highly resistant bacteria and the leading cause of hospital-acquired infections globally. About the author James Graham, CEO of Recce Pharmaceuticals Recce Pharmaceuticals.
In case you haven’t noticed, private equity firms have displaced hospitals and health systems as the major acquirers of community oncology practices. Future Trends for Buy-and-Bill Channels) of our new our 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , now available to download at special launch pricing.
19, 2020 — Children with autism spectrum disorder (ASD) and/or attention-deficit/hyperactivity disorder ( ADHD ) have more doctor and hospital visits during infancy, according to a study published online Oct. ” Two authors disclosed financial ties to the pharmaceutical industry. . MONDAY, Oct. 19 in Scientific Reports.
Meanwhile, consumers shoulder a much higher portion of this spending compared with their share of hospital spending. Demonizing pharmaceuticals as a driver of U.S. What's more, drug spending again grew more slowly than overall healthcare spending. healthcare spending growth is simply inaccurate.
Below, I include links to publicly available comments from a diverse range of stakeholders, including 340B Health, the American Hospital Association, Biotechnology Innovation Organization, Community Oncology Alliance, National Association of Community Health Centers, and Pharmaceutical Research and Manufacturers of America.
Consider two apparently unrelated drug channel anomalies: In McKesson’s 2023 fiscal year, CVS bought $75 billion in pharmaceuticals from McKesson’s wholesale business—a jump of more than 35% compared with the previous year. Despite skyrocketing sales for anti-obesity GLP-1 drugs, many retail pharmacies are losing money on every prescription.
Consider two apparently unrelated drug channel anomalies: In McKesson’s 2023 fiscal year, CVS bought $75 billion in pharmaceuticals from McKesson’s wholesale business—a jump of more than 35% compared with the previous year. Despite skyrocketing sales for anti-obesity GLP-1 drugs, many retail pharmacies are losing money on every prescription.
A new shift is occurring in the pharmaceutical industry, leading to a rapidly expanding field known as digital therapeutics (DTx). DTx interventions include sensor-equipped wearable devices, remote patient monitoring tools, and virtual reality platforms integrated with conventional pharmaceutical treatments.
17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. ,
Another key difference with industry is the close partnership with the Royal Marsden Hospital, the first hospital in the world dedicated to cancer diagnosis, treatment, research and education. Both of the ICR’s research laboratory sites in Sutton and in Chelsea are in close proximity to the Royal Marsden Hospital sites.
27, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. Dr. Hasan Jafri , Chief Medical Officer of Aridis Pharmaceuticals, will be a speaker on a panel entitled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus.” About Aridis Pharmaceuticals, Inc. Aridis Pharmaceuticals, Inc. SAN JOSE, Calif. ,
Regeneron announced today an update from the independent data monitoring committee (DMC) for the United Kingdom-based RECOVERY trial evaluating REGN-COV2 in hospitalized patients with COVID-19.
In Australia, both methadone and buprenorphine have been subsidised by the Pharmaceutical Benefit Scheme (PBS) for the treatment of opioid dependence (termed ‘opioid agonist treatment’ or OAT) for several decades. In September 2019, a new formulation of long-acting injectable buprenorphine became available on the PBS.
Regeneron Pharmaceuticals, Inc. NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified. About the REGN-COV2 Trial in Hospitalized Patients. TARRYTOWN, N.Y. ,
distribution and dispensing channels for prescription drugs are undergoing significant evolution and consolidation as the changing economics of pharmaceuticals challenge conventional business models. As regular readers of Drug Channels know, U.S. Put simply: Buy low, sell high, collect early, and pay late. drug wholesaling industry.
To more precisely define cellular drivers of RA, an international research consortium co-led by researchers from the Broad Institute of MIT and Harvard and Brigham and Women’s Hospital analyzed tissues from RA donors at the single-cell level, integrating multiple forms of analysis to stratify RA by six subtypes of inflammation.
25, 2020 /PRNewswire/ — Vivera Pharmaceuticals and Burkhan World today announce financial backing by JR Dallas Wealth Management in support of Vivera’s global growth strategies. “Our new partner, Vivera Pharmaceuticals, is the ideal strategic partner for our vision to make a difference in peoples’ lives.”
“Receiving Fast Track designation is an important acknowledgment of the results of our COVID-19 laboratory research,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at: [link].
Source link.
21, 2020 (GLOBE NEWSWIRE) — Shanghai Haini Pharmaceutical Co., They are one of the top pharmaceutical firms in China and are considered a market leader in the antibiotics space. About YRPG
Yangtze River Pharmaceutical Group (YRPG) was founded in 1971, which is headquartered in Taizhou, China.
Licenses for our DCI reports are regularly purchased by nearly every company involved in the drug channel: pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, hospitals, buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and more.
In case you haven’t noticed, private equity firms have displaced hospitals and health systems as the major acquirers of community oncology practices. Future Trends for Buy-and-Bill Channels) of our new our 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , now available to download at special launch pricing.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content